Trial · NCT07903909
Effect of Cholecalciferol on Mucin-1 Levels in Urinary Extracelllular Vesicles in Individuals With Autosomal Dominant Tubulo-Interstitial Kidney Disease Due to MUC1 Mutations (ADTKD-MUC1)
NCT07903909, Not applicable, Completed, Gregory Papagregoriou
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of Cholecalciferol on Mucin-1 Levels in Urinary Extracelllular Vesicles in Individuals With Autosomal Dominant Tubulo-Interstitial Kidney Disease Due to MUC1 Mutations (ADTKD-MUC1). Trials, record NCT07903909. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07903909
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of Cholecalciferol on Mucin-1 Levels in Urinary Extracelllular Vesicles in Individuals With Autosomal Dominant Tubulo-Interstitial Kidney Disease Due to MUC1 Mutations (ADTKD-MUC1)
- NCT number
- NCT07903909
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 75 participants, actual
- Lead sponsor
- Gregory Papagregoriou
- Conditions
- Tubulointerstitial Kidney Diseases, MUC1 Kidney Disease
- Interventions
- Cholecalciferol (Vit D3)
- First posted
- 2026-10-29
- Last updated
- 2026-10-29
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | MUC1 and MUC1-fs peptide measurement in urinary extracellular vesicles | From enrollment (Day -10) to end of treatment (Day 30), total 40 days | The primary objective of this study is to determine if a one-time oral administration of 200,000 units of cholecalciferol results in a statistically significant decrease in urinary EVs mucin-1 (MUC1 and MUC1-fs) levels at days 3 and 7 after supplement administration in 46 patients with ADTKD-MUC1, compared to baseline levels of urine samples collected at day-10 and day 0 and samples and protein levels during the recovery period at days 10, 14 and 30 post administration. 29 controls will be used as a comparator cohort to identify early clinical responses. |
| Secondary | Reduction in serum CA15-3 levels compared to uEVs | From enrollment (Day -10) to end of treatment (Day 30), total 40 days | 1. To determine if 200,000 units of cholecalciferol result in a statistically significant change in MUC1 and MUC1-fs levels found in plasma EVs measured by iMRM proteomics at days 7 and 14, compared to baseline levels at day 0. 2. To determine if 200,000 units of cholecalciferol result in a statistically significant decrease in serum MUC1 levels (CA15-3) measured by ELISA or at a clinical lab at days 7 and 14, compared to baseline levels at day 0. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 31348885 | BACKGROUND |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07903909
GET https://conductscience.org/api/trials/v1/NCT07903909/registered